Findings are preliminary, but show promise; not controlled trial, not randomized treatement

The authors say TCZ treatment may be good option for patients for whom other treatments have not worked.

Laboratory measures showed hyperinflammatory state, but it did not necessarily meet requirements to be considered s secondary hemophagocytic lymphohistiocytosis (sHLH

"CRP, ferritin and fibrinogen serum levels decreased toward the normal range and lymphocyte count increased, especially in patients whose clinical conditions improved."

"IL-6 serum levels increased, similarly to what was reported after TCZ administration in patients with Rheumatoid Arthritis and Castleman disease."

"D-Dimer levels remained high, suggesting that TCZ was able to act only partially on the inflammatory cascade and might have had a minimal or no effect on down-modulating active coagulation"